ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model

ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro

(2016) Eric M. Ostertag et al.   TRANSFUSION

ADAMTS13 and von Willebrand Factor in Thrombotic Thrombocytopenic Purpura

(2015) X. Long Zheng   Annual Review of Medicine

How I treat refractory thrombotic thrombocytopenic purpura

(2015) Farzana A. Sayani et al.   BLOOD

High-resolution epitope mapping by HX MS reveals the pathogenic mechanism and a possible therapy for autoimmune TTP syndrome

(2015) Veronica C. Casina et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic thrombocytopenic purpura in mice

(2014) Y. Morioka et al.   BLOOD

AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura

(2013) S.-Y. Jin et al.   BLOOD

Animal models for thrombotic thrombocytopenic purpura

(2013) K. Vanhoorelbeke et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Novel Antiplatelet Agents: ALX-0081, a Nanobody Directed towards von Willebrand Factor

(2013) Jozef Bartunek et al.   Journal of Cardiovascular Translational Research

Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons

(2012) H. B. Feys et al.   BLOOD

A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13

(2012) A. Schiviz et al.   BLOOD

Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura

(2012) C. Jian et al.   BLOOD

Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse

(2012) J-P. Westwood et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Generation and Breakdown of Soluble Ultralarge von Willebrand Factor Multimers

(2012) Nancy Turner et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice

(2011) Junmei Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies

(2011) B. PLAIMAUER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus)

(2010) H. B. Feys et al.   BLOOD

Hydrodynamic Gene Delivery and Its Applications in Pharmaceutical Research

(2010) Barbara Bonamassa et al.   PHARMACEUTICAL RESEARCH

The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo

(2010) Florian B. Mayr et al.   TRANSFUSION

Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy

(2009) P. Laje et al.   BLOOD

Survival and relapse in patients with thrombotic thrombocytopenic purpura

(2009) J. A. K. Hovinga et al.   BLOOD

Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots

(2008) M. Neyman et al.   BLOOD

ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission

(2008) F. Peyvandi et al.   HAEMATOLOGICA

ADAMTS13: a new link between thrombosis and inflammation

(2008) Anil K. Chauhan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis

(2007) A. K. Chauhan et al.   BLOOD